CARE Carter Bankshares Forecast, Technical & Fundamental Analysis

CARE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CARE turned positive on October 02, 2026. Looking at past instances where CARE's MACD turned positive, the stock continued to rise in 29 of 37 cases over the following month. The odds of a continued upward trend are 78%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 59 cases where CARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Following a +2.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARE advanced for three days, in 215 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

CARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CARE as a result. In 47 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

The Aroon Indicator for CARE entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock better than average.

The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.274) is normal, around the industry mean (1.321). P/E Ratio (5.110) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (1.186). CARE has a moderately low Dividend Yield (0.007) as compared to the industry average of (0.030). P/S Ratio (3.140) is also within normal values, averaging (3.747).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.